Preliminary real-world evidence is provided that OBT-A treatment is associated with improved subjective sleep quality in patients with chronic migraine and the mechanisms underlying sleep improvement are still unclear, although the lack of statistical significance warrants cautious interpretation.
Abstract
Sleep disturbances are highly prevalent in patients with chronic migraine (CM) and are increasingly recognized as major contributors to disease burden and headache chronification. Growing evidence suggests that dysregulation of calcitonin gene-related peptide (CGRP) signaling and central sensitization may represent common biological mechanisms linking migraine and sleep impairment. OnabotulinumtoxinA (OBT-A), an established preventive treatment for CM, inhibits the release of CGRP and other nociceptive mediators from trigeminal sensory neurons, thereby reducing peripheral and central sensitization. However, its effects on sleep quality remain incompletely characterized. The aim of this prospective real-world observational pilot study was to evaluate the impact of OBT-A treatment on sleep quality in patients with CM. Consecutive patients initiating OBT-A therapy at a tertiary headache center were enrolled and assessed at baseline (before the first OBT-A treatment cycle) and after three months, immediately before the second scheduled administration, using the Pittsburgh Sleep Quality Index (PSQI), alongside measures of migraine frequency, acute medication use, migraine-related disability, and headache impact. Fifteen patients completed follow-up evaluations. OBT-A treatment was associated with significant improvements across all clinical outcomes. Median monthly migraine days decreased from 18 to 10 (adjusted p = 0.006), while acute medication use, MIDAS scores, and HIT-6 scores were significantly reduced. Sleep quality improved markedly, with median PSQI scores decreasing from 10 to 6 (adjusted p = 0.006). Eleven of 15 patients (73.3%) achieved a ≥3-point reduction in PSQI, and the proportion of participants with pathological sleep quality (PSQI > 5) decreased from 86.7% to 53.3%. Although this categorical improvement did not reach statistical significance (exact p = 0.063), likely due to the limited sample size, it may nonetheless suggest a beneficial effect on sleep quality, although the lack of statistical significance warrants cautious interpretation. These findings provide preliminary real-world evidence that OBT-A treatment is associated with improved subjective sleep quality in patients with chronic migraine. Improvements in sleep quality occurred alongside reductions in migraine frequency, acute medication use, disability, and headache impact. Given the observational and uncontrolled design of the study, it remains unclear whether sleep improvement reflects a direct effect of OBT-A or occurs secondarily to improvements in migraine-related outcomes. Larger prospective controlled studies are needed to clarify the mechanisms underlying sleep improvement and its relationship with treatment response.
Background. Chronic migraine is one of the leading causes of neurological disability, significantly affecting quality of life and daily functioning. Despite the availability of conventional and advanced preventive treatments, including anti-CGRP monoclonal antibodies and botulinum toxin type A, many patients continue t...
Background Migraine represents one of the most disabling neurological disorders, frequently underdiagnosed and undertreated, with predominant reliance on acute medications that may precipitate medication overuse headache. Evidence indicates that triptans, including naratriptan, modulate central sensitization—a key path...
Luana Zanoni Schauffer, M. Peres, Marina Luiza Veloso Ferreira et al.· Headache Medicine· 0 citations
Sensory-mediated therapy using Viola odorata L. and oral administration of Papaver somniferum L. seeds are effective in the management of primary insomnia, with combination therapy providing additive sustained with less recurrence rate and supporting a graded, personalized integrative treatment approach.
Huma Rafiq, Arif Habib, T. A. Rafeeqi et al.· Sleep Science and Practice· 0 citations
It is demonstrated that ashwagandha supplementation leads to statistically significant improvements in sleep metrics and that Ashwagandha’s most profound impact on sleep architecture is driven by its interactions with the GABAergic pathway.
A. Wielogórska, Aleksander Kamecki, Zuzanna Rak et al.· International Journal of Inn...· 0 citations
OBJECTIVE
To evaluate a GABAergic, melatonergic, and glutamatergic supplement for enhancing sleep quality in perimenopausal and postmenopausal women with low vasomotor symptom (VMS) burden.
METHODS
A randomized, double-blind, placebo-controlled, decentralized trial (NCT07375095) was performed in healthy perimenopausa...
Stephen Carbonneau, Vincent Mysliwiec, Audra Lisa Doyle et al.· Menopause· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.